DAEDALUS is a Horizon Europe-funded research project aiming to transform the treatment of colorectal diseases (CRDs) through a new generation of minimally invasive, regenerative solutions. These diseases, such as ulcerative colitis and familial adenomatous polyposis, currently require invasive surgery with serious long-term consequences.
DAEDALUS proposes an alternative: the replacement of damaged tissues using injectable 4D biomaterials, enriched with therapeutic molecules and patient-derived cells. The goal is to restore tissue function while reducing complications and improving quality of life.
ThioMatrix brings its expertise in advanced drug delivery systems to support the formulation of smart therapeutic components in the DAEDALUS biomaterials. The team also leads the project’s regulatory strategy and contributes to scaling up production of materials from lab to preclinical stages. Learn more
:focal())